目的 :比较青霉素 V钾胶囊与片剂的药物动力学及相对生物利用度。方法 :以微生物法测定 10名健康受试者单次空腹 po青霉素 V钾胶囊和片剂 5 0 0 m g后血、尿药浓度。结果 :po青霉素 V钾胶囊和片剂后的体内过程符合二室模型 ,其平均cmax分别为 ( 8.2 2± 1.2 1)和 ( 7.71± 1.0 9) mg/ L,tmax为 ( 0 .5 5± 0 .11)和 ( 0 .5 8± 0 .17) h,T1 /2 ka为 ( 0 .2 1± 0 .0 9)和 ( 0 .2 0± 0 .0 6 )h,T1 /2β为 ( 0 .81± 0 .2 1)和 ( 0 .72± 0 .0 8) h,AUC为 ( 9.5 1± 1.0 6 )和 ( 9.5 0± 1.82 ) h· mg/ L,2 4h累积尿排出率分别为给药量的 ( 35 .33± 7.45 ) %和 ( 37.80± 5 .45 ) %。青霉素 V钾胶囊与片剂的药物动力学参数间差异无统计学意义 ( P>0 .0 5 )。结论 :青霉素 V钾胶囊的相对生物利用度为 ( 10 1.44± 9.5 9) % ,与片剂具生物等效性 Objective: To compare the pharmacokinetics and relative bioavailability of penicillin V potassium capsules and tablets. Methods: The blood and urine concentrations of 10 healthy volunteers were determined by microbiological method after a single fasting po penicillin V potassium capsules and 500 mg tablets. RESULTS: The in vivo process of po penicillin V potassium capsules and tablets conformed to the two-compartment model with mean cmax of (8.22 ± 1.2 1) and (7.71 ± 1.09) mg / L, respectively, with a tmax of (0.55 ± 0 .11) and (0.58 ± 0.17) h, T1 / 2 ka was (0.21 ± 0.09) and (0.2 ± 0.06) h, T1 / 2β (0.81 ± 0.21) and (0.72 ± 0.08) h, the AUCs were (9.5 ± 1.06) and (9.5 ± 1.82) h · mg / L, respectively. The discharge rates were (35.33 ± 7.45)% and (37.80 ± 5.45)%, respectively. There was no significant difference in pharmacokinetic parameters between penicillin V potassium capsules and tablets (P> 0.05). Conclusion: The relative bioavailability of penicillin V potassium capsule was (10 1.44 ± 9.5 9)%, which was bioequivalent to tablets